MedTrace Logo

Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease

NCT04988282 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 262

Last updated 2023-10-10

No results posted yet for this study

Summary

Aim: To investigate the efficacy of systemic corticosteroids in treatment for Post-COVID-19 Interstitial Lung Disease.

Method: Method: In this multi-centre, prospective, randomised controlled open label clinical trial, patients are divided into two arms: standard treatment arm and standard plus systemic corticosteroid arm. After twelve weeks; clinical, functional, and radiological improvement will being assessed as primary outcomes.

Conditions

Interventions

DRUG

Methylprednisolone Tablet

Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks

Sponsors & Collaborators

  • Turkish Thoracic Society

    lead OTHER

Principal Investigators

  • METİN AKGÜN · ATATURK UNIVERSITY FACULTY OF MEDICINE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2021-12-31
Completion
2022-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04988282 on ClinicalTrials.gov